linjc16/ctgov huggingface dataset:
Testing the Efficiency of Karman Curette in the Treatment of Misoprostol Failure in Women With Missed Abortion

Study Overview
=================
Brief Summary
-----------------
the purpose of this study is to examine the success rates of Karman curettage in completing the abortion after failed recurred treatment with Misoprostol for women with missed abortion.

Conditions
-----------------
Abortion, Missed

Intervention / Treatment
-----------------
* Device: Karman curettage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy women diagnosed with missed abortion treated in Meir Medical Center. The abortion occured during the first trimester of pregnancy. Patients who chose drug therapy (Misoprostol), after retained products of conception were evident on ultrasound. Exclusion Criteria: patients with mullarian abnormality (i.e. septal uterus, myoma etc.) patients with significant bleeding Endometrial wall (residua) greater than 20 mm. known or suspected infection known clotting defect women after cesarean section closed cervix

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Karman curettage<br>after a retained product of interception is observed in ultrasound examination, the women in this arm will undergo Karman curretage. | Device: Karman curettage<br> <br> |
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Completing the abortion | completing the abortion until the scheduled day for hysteroscopy, thus preventing the need for hysteroscopy | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of days of bleeding | asking the patient how many days of bleeding did she have after the procedure | 3 months | 
| pregnancy | asking the patient if she is currently pregnant | 3 months | 
| Pain intensity | asking the patient about the intensity of the pain during and after the procedure, as measured with NRS-11 pain scale | 3 months | 
| infection | asking the patient if she was diagnosed with any infection signs | 3 months | 
| number of sick days | asking the patients how many sick leave days did she take | 3 months | 
| number of days of abstinence from sexual intercourse | asking the patient how many days did she abstain from sexual intercourse after the procedure | 3 months |
Longitudinal Survey Analysis in Lymphoma Survivors

Study Overview
=================
Brief Summary
-----------------
Posttraumatic Stress Disorder (PTSD) is a well-documented phenomenon that occurs in cancer survivors. PTSD is known to cause problems with anxiety, depression, and quality of life. Furthermore, there is little treatment available for cancer survivors who suffer from PTSD. Posttraumatic Growth, however, is a lesser known phenomenon that also occurs in cancer survivors. It is a positive psychological phenomenon that occurs in some people who have suffered a traumatic event--the people who are able to note a greater appreciation for life, a stronger relationship with their family/friends, or a new found level of spirituality are examples of instances of posttraumatic growth. Coping with Lymphoma to Enhance Adjustment and Reduce Stress in Survivors (CLEAR Stress) is a study designed to compare the development of PTSD versus the development of Posttraumatic Growth in lymphoma patients at any stage of the cancer experience, regardless of treatment. The hypothesis is that posttraumatic growth, if it is significant, can reduce the impact of PTSD symptoms in the survivor.

Official Title
-----------------
Coping With Lymphoma to Enhance Adjustment and Reduce Stress in Lymphoma Survivors

Conditions
-----------------
Lymphoma, Coping, Posttraumatic Stress Disorder, Posttraumatic Growth, Resilience

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Lymphoma (includes Waldenstrom's Macroglobulinemia) Can read/write/understand English without a translator Exclusion Criteria: Currently Hospitalized Active Psychosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lymphoma Survivors<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Posttraumatic Growth |  | Measured at enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Posttraumatic Stress Disorder (PTSD) |  | Measured at Enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lymphoma, survivors, posttraumatic growth, posttraumatic stress, longitudinal
Alternate Day Buprenorphine Administration, Phase XI - 16

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate open buprenorphine dosing with dose choice after open exposure.

Official Title
-----------------
Alternate Day Buprenorphine Administration, Phase XI

Conditions
-----------------
Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 51 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Crossover Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug use |  |  | 
| Opioid withdrawal |  |  | 
| Opioid agonist effects |  |  | 
| Dose choice |  |  |
NGS vs Culture Outcomes for Treatment of PJI

Study Overview
=================
Brief Summary
-----------------
This multicenter, randomized controlled trial will compare the use of NGS and traditional culture in directing antimicrobial treatment for patients with periprosthetic joint infection.

Official Title
-----------------
Randomized Controlled Trial Investigating the Use of Next-generation Sequencing in Directing the Antimicrobial Treatment of Periprosthetic Joint Infection

Conditions
-----------------
Prosthetic Joint Infection

Intervention / Treatment
-----------------
* Diagnostic Test: Culture-based treatment
* Diagnostic Test: Next Generation Sequencing (NGS) with Culture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults (age > 18 years) Undergoing single stage revision or 1st stage resection arthroplasty/spacer placement for PJI (ICM-positive) of the hip or knee Written informed consent Exclusion Criteria: Ongoing participation in another clinical trial Megaprosthesis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Culture-based treatment<br> | Diagnostic Test: Culture-based treatment<br>* Medications to treat prosthetic joint infection will be chosen based on results of traditional cultures alone<br>|
| Active Comparator: Next Generation Sequencing (NGS) with Culture-based treatment<br> | Diagnostic Test: Next Generation Sequencing (NGS) with Culture<br>* Medications to treat prosthetic joint infection will be chosen based results of NGS and culture<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants who have been diagnosed with prosthetic joint infection as assessed by the 2018 International Consensus Definition of prosthetic joint infection | Diagnosis of re-infection following surgery and treatment for prosthetic joint infection | 90 days from time of surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects who have a re-operation as assessed by inpatient hospitalization medical records |  | one year from time to surgery |
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Study Overview
=================
Brief Summary
-----------------
This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).

Official Title
-----------------
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer

Conditions
-----------------
Non Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: STA 9090


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV NSCLC with measurable disease by RECIST and evidence of progression Availability of tissue for analysis ECOG Performance Status 0 or 1 Adequate organ function as defined in the protocol. Must be at least 18 years old and able and willing to sign a written informed consent document Exclusion Criteria: Poor venous access requiring an indwelling catheter for study drug administration Women who are pregnant or lactating Ventricular ejection fraction < or = to 55% at baseline Any uncontrolled intercurrent illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: STA 9090<br>* STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression Free Survival rate |  | 16 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Response Rate, Disease Control Rate, Progression Free Survival, Overall Survival |  | 18 months | 
| Safety and tolerability as measured by adverse event rates and laboratory evaluations |  | 16 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Synta, STA 9090, ganetespib), Lung Cancer, Non Small Cell Lung Cancer, NSCLC
Sex-related Differences in Sympathetic Vascular Transduction in the Setting of Hypoxemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this project is to identify sex-related differences in the effect of hypoxia on sympathetic vascular transduction.

Official Title
-----------------
Sex-related Differences in Sympathetic Vascular Transduction in the Setting of Hypoxemia

Conditions
-----------------
Vasodilation, Hypoxia

Intervention / Treatment
-----------------
* Drug: Propranolol Pill
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy adult men and women; 18-45 years of age; BMI 18-30 kg/m2; non-pregnant/non-breastfeeding; non-nicotine users; Exclusion Criteria: Pregnancy, breastfeeding, hormonal contraceptives Diagnosed sleep apnea Current smoking/Nicotine use/drug use Nerve/neurologic disease Cardiovascular, hepatic, renal, respiratory disease Blood pressure ≥140/90 mmHg Diabetes, Polycystic ovarian syndrome Communication barriers Prescription medications Recent COVID-19 diagnosis with symptoms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Hypoxia Exposure<br>Men and women will be exposed to isocapnic hypoxia. Participants will wear a mask and systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry. | Drug: Propranolol Pill<br>* Participants will receive a β-blockade (propranolol pill, 1 mg/kg dosed based on participant weight).<br>Drug: Placebo<br>* Participants will receive a placebo in pill form.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Forearm Blood Flow | Measured with venous occlusion plethysmography (mL/dL/min) | Change from baseline to 5 minutes |
Changes of Microbiota in Irritable Bowel Syndrome Patients

Study Overview
=================
Brief Summary
-----------------
To investigate the changes of gastrointestinal microbiota in irritable bowel syndrome patients by hydrogen breath test and molecular-based analysis of microbiota in gastrointestinal tract

Conditions
-----------------
Mucosa Associated Bacteria in Small Intestine

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Case group: 20 to 80 years old irritable bowel syndrome patients Control group: 20 to 80 years old healthy subjects Exclusion Criteria: without writtent informed consent contraindications for enteroscopy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| irritable bowel syndrome patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| difference in component of microbiota between cases and controls |  |  |
Impact of a Financial Success Education Program in Women and Children

Study Overview
=================
Brief Summary
-----------------
Many Americans are living paycheck to paycheck. This may lead to financial stress and an increase in overall stress. People under stress are more likely to smoke, consume alcohol, eat a poor diet, and experience depression or anxiety. Experiencing financial stress may also increase the risk for heart disease. The purpose of this research study is to test whether participating in the Financial Success Program improves health outcomes, in both the women participating and their children.

Official Title
-----------------
Impact of a Financial Success Education Program on Perceived Financial Well-being, Hopefulness, Financial Competency, Financial Goal Achievement, Quality of Life, and Quantitative Health Outcomes in Women and Children: A Pilot Study

Conditions
-----------------
Stress

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women 19 years or older enrolled in the Financial Success Program in fall 2011 and winter 2012 and/or a their child(ren) ages 3-18 years attending the daycare with their mother Women must be employed to be enrolled in the Financial Success Program Able and willing to provide informed consent Exclusion Criteria: Women less than 19 years of age Women working a night time shift (due to variability in diurnal cortisol secretion) Known pregnancy or planned pregnancy (due to variability in blood pressure, glucose, weight, and lipids) Women are excluded from the Financial Success Program if they are living in a domestic violence situation or abusing alcohol or illicit drugs

Ages Eligible for Study
-----------------
Minimum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Minutes of Exercise Per Week | Mean minutes of exercise per week | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fast Food Meals Per Week | Mean number of fast food meals per week | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
low socioeconomic status, stress, women, children, cortisol
Comparison of Infiltration Analgesia With Femoral Nerve Block After Hamstrings Anterior Cruciate Ligament Reconstruction

Study Overview
=================
Brief Summary
-----------------
Pain treatment after anterior cruciate ligament reconstruction - Comparison of infiltration analgesia with femoral nerve block after.

Detailed Description
-----------------
Inclusion Criteria: Patients undergoing primary anetrior cruciate ligament reconstruction with semiTendinos/gracillis graft Age > 18 year Exclusion Criteria: Revision ACL reconstruction Patients with cartilige lision Patients with arthritis Pregnant women.

Official Title
-----------------
Pain Treatment After Anterior Cruciate Ligament Reconstruction

Conditions
-----------------
Injury of Anterior Cruciate Ligament

Intervention / Treatment
-----------------
* Procedure: Femoral nerve block
* Procedure: Local infiltration analgesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing primary anetrior cruciate ligament reconstruction with semiTendinos/gracillis graft Age > 18 year Exclusion Criteria: Revision ACL reconstruction Patients with cartilige lision Patients with arthritis Pregnant women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Naropin, Adrenalin, applicationsite<br> | Procedure: Local infiltration analgesia<br>* Local infiltration analgesia with ropivacaine 2.5mg/ml with epfinedrine 5mikrogram/ml. 20ml at harvest site and 20ml at incisionsites.<br>* Other names: LIA teknik;|
| Active Comparator: Femoral nerve block<br> | Procedure: Femoral nerve block<br>* Femoral nerve block ultrasound guidet with ropivacaine 20ml 2.5mg/ml<br>* Other names: FNB;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numeric Rang Scale pain |  | 1 day after operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| use of analgetics |  | 0h, 3h, 24h, 48h |
Different Crystalloids on AKI in Shock

Study Overview
=================
Brief Summary
-----------------
The goal is to observe that the incidence of acute kidney injury in patients who need fluid resuscitation when resuscitated with saline or acetated Ringer's sodium.

Detailed Description
-----------------
Fluid resuscitation is important to shock patients. Saline is the classical fluids for resuscitation. However, studies showed that resuscitation with saline could increase the incidence of hyperchloremia and acute kidney injury. Thus, the goal is to observe that the incidence of acute kidney injury in patients who need fluid resuscitation when resuscitated with saline or acetated Ringer's sodium.

Official Title
-----------------
The Effect of Different Crystalloids on the Incidence of Acute Kidney Injury in Shock Patients

Conditions
-----------------
Shock

Intervention / Treatment
-----------------
* Other: Fluid resuscitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Shock patients who need fluid resuscitation with risk factors of acute kidney injury Exclusion Criteria: Patients with a history of chronic kidney injury and hemodialysis therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Saline group<br>Patients resuscitated with saline | Other: Fluid resuscitation<br>* Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium<br>|
| Acetated Ringer's sodium group<br>Patients resuscitated with Acetated Ringer's sodium | Other: Fluid resuscitation<br>* Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of acute kidney injury | Incidence of acute kidney injury | 28 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Application of renal replacement | Application of renal replacement | 28 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
shock, acute kidney injury, crystalloid